REGULATORY
CDP OKs Bill to Scrap Off-Year Revisions, Aims for Diet Submission Soon
By Ken Yoshino December 13, 2024
Japan’s main opposition party, the Constitutional Democratic Party of Japan (CDP), on December 12 approved a draft bill to make drug price revisions a biennial event, effectively blocking off-year revisions except in special cases.The lawmaker-sponsored…

LATEST

December 13, 2024
RaQualia Pharma said on December 12 that its acid reducer tegoprazan was launched in five Latin American countries through Mexican sublicensing partner Carnot. With this, the drug is now available in a total of 15 nations worldwide.The five markets added…
December 12, 2024
Daiichi Sankyo said on December 10 that the first patient has been dosed with its FLT3 inhibitor Vanflyta (quizartinib) in a global PIII trial including Japan for the first-line treatment of patients with newly diagnosed…
December 12, 2024
The European Federation of Pharmaceutical Industries and Associations, Japan (EFPIA Japan) on December 11 released a joint statement with patient groups on the issues of drug lags and losses and access to clinical trial information.In…
By Tatsuya Otsuka

The average gap between NHI prices and the market prices of listed medicines in Japan stood at a preliminary 5.2%…

By Philip Carrigan

For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…

A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…

The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA